Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma.

Abstract

The authors describe a case of an 8-month-old boy with opsoclonus-myoclonus syndrome (OMS) and coincident unresectable neuroblastoma (NB). He achieved a complete remission for NB after 6 courses of standard-dose chemotherapy without significant neurological improvement despite the use of steroids and high-dose immunoglobulin (HIG), administered separately. Only the combined treatment withthese two drugs induced a complete disappearance of neurological symptoms. On the basis of this experience, the authors suggest the association of steroids plus HIG for the treatment of OMS in patients not responsive to conventional first line therapy with steroids.

• Authors: E Veneselli, M Conte, R Biancheri, A Acquaviva, B De Bernardi
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 30 Issue 1 Pg. 15-7 (Jan 1998) ISSN: 0098-1532 [Print] United States
• PMID: 9371383 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Hormonal
• Dexamethasone

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Dexamethasone (therapeutic use)
• Humans
• Immunization, Passive (methods)
• Infant
• Male
• Myoclonus (drug therapy, etiology, therapy)
• Neuroblastoma (complications, drug therapy, therapy)
• Ocular Motility Disorders (drug therapy, etiology, therapy)
• Syndrome